Cipla Ltd. — Capital/Financing Update 2020

Apr 2, 2020

2[nd] April 2020

(1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai - 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA EQ

• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Press Release - Successful completion of Phase-3 clinical study for generic version of GSK’s Advair Diskus®

Dear Sir/Madam,

Please find enclosed press release dated 2[nd] April 2020 for the captioned subject.

Kindly acknowledge the receipt

Thanking you,

Yours faithfully,

For Cipla Limited

Digitally signed by RAJENDRA CHOPRA DN: c=IN, o=Personal, 2.5.4.20=4987ad48c3965cfde78c8ea69e6 RAJENDRA f40ac91535876f12ba1fa5ba45cc5cc8db6 cb, postalCode=122001, st=HARYANA, serialNumber=0be85c0408d0e3afd66366 CHOPRA 9f5314248a72fdcdf34d01d48d472d7cf9262696f6, cn=RAJENDRA CHOPRA Date: 2020.04.02 08:19:33 +05'30' Rajendra Chopra Company Secretary

Encl: as above

Prepared by: Juzer Masta

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India. Phone : +91 2224826000 Fax : +9122 24826120 Website: www.cipla.com Email : contanctus@cipla.com Corporate Identity Number: L24239MH1935PLC002380

==> picture [159 x 87] intentionally omitted <==

Press Release

Cipla announces successful completion of Phase-3 clinical study for generic version of GSK’s Advair Diskus[® ]

Achieves a significant milestone towards strengthening its regulated markets

Respiratory franchise

Mumbai, India; April 02, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced the successful completion of Phase-3 clinical end-point study for fluticasone propionate and salmeterol inhalation powder (100/50 mcg).

Fluticasone propionate and salmeterol inhalation powder 100/50 mcg, 250/50 mcg and 500/50 mcg are generic versions of GSK’s Advair Diskus®. The product is indicated to treat asthma in patients 4 years and older as a twice-daily prescription medicine and in long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups.

The Phase-3 study, successfully completed in the first attempt, was conducted over a period of 15 months at over 100 sites in the US enrolling 1400 asthma patients. The study results demonstrate that Cipla’s fluticasone propionate and salmeterol inhalation powder 100/50 mcg is therapeutically equivalent to Advair Diskus® 100/50mcg. The study demonstrated therapeutic equivalence by assessing the primary end points which is in accordance with regulatory recommendations and guidelines. There were no safety concerns identified during the trials.

Commenting on the trial completion, Umang Vohra (MD and Global CEO, Cipla, Limited) said “I am extremely pleased with the successful completion of the Phase-3 clinical study of generic Advair Diskus®. Considering the complexity of clinical endpoint study in the Fluticasone + Salmeterol combination, it is heartening to see that our study was successful in the first attempt. This is an important milestone and is a testament to Cipla’s strong respiratory capabilities and will go a long way in strengthening our respiratory franchise in the US. Unmatched presence across the care continuum and the widest range of drug-device combinations has established Cipla’s position as a lung leader in India and other key emerging markets. Our endeavour is to extend this expertise across developed markets through niche product development.”

According to IQVIA (IMS Health), Advair Diskus® and its generic equivalents had US sales of approximately US$2.9bn for the 12-month period ending February 2020.

About Cipla :

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Feb’20), 3rd largest in the pharma private market in South Africa (IQVIA MAT Feb’20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigmchanging offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact :

Corporate Communications Investor Relations

Heena Kanal Naveen Bansal

E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com